ReviewImmunologic research2010
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
Review in Immunologic research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Ex vivo expansion and hydrogel-mediated in vivo delivery of tissue-resident memory T cells for immunotherapy.Science advances · 2024Article
- MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.Frontiers in immunology · 2023Article
- Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems.Biomaterials research · 2022Article
- Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.Biomaterials · 2021Review
- Soluble MHC class I complexes for targeted immunotherapy.Life sciences · 2018Review
- Review: Bioengineering strategies to probe T cell mechanobiology.APL bioengineering · 2018Review
- Engineering Platforms for T Cell Modulation.International review of cell and molecular biology · 2018Review
- Article
- Surface engineering for lymphocyte programming.Advanced drug delivery reviews · 2017Review
- Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.Biomaterials · 2017Article
- The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.Journal of immunology research and therapy · 2017Article
- Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Theranostics · 2017Review
- CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Linking form to function: Biophysical aspects of artificial antigen presenting cell design.Biochimica et biophysica acta · 2015Review
- Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.Trends in biotechnology · 2014Review
- Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.Nature protocols · 2014Article
- Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.ACS nano · 2014Article
- Nanoscale artificial antigen presenting cells for T cell immunotherapy.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Modulation of MHC binding by lateral association of TCR and coreceptor.Biophysical journal · 2012Article
- Artificial antigen-presenting cells for use in adoptive immunotherapy.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent advances in molecular medicine have shown that soluble MHC-multimers can be valuable tools for both analysis and modulation of antigen-specific immune responses in vitro and in vivo. In this review, we describe the use of dimeric human and mouse major histocompatibility complexes, MHC-Ig, as part of an artificial Antigen-Presenting Cell (aAPC). MHC-Ig-based aAPC and its derivatives represent an exciting new platform technology for measuring and manipulating immune responses in vitro as well as in vivo. This new technology has the potential to help overcome many of the obstacles associated with limitations in current antigen-specific approaches of immunotherapy for the treatment of cancer, infectious diseases and autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.